Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, Bakken CL, Grønningsæter SR, Bruland ØS, Larsen RH, Bouzelmat L, Jardine VL, Stokke C(2025) First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer J Nucl Med(in press) DOI 10.2967/jnumed.124.269299, PubMed 40081958
Hompland I, Boye K, Wiedswang AM, Papakonstantinou A, Røsok B, Joensuu H, Bruland Ø(2024) Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study Acta Oncol, 63, 288-293 DOI 10.2340/1651-226X.2024.39851, PubMed 38712513
Larsen SG, Graf W, Larsen RH, Revheim ME, Mariathasan AM, Sørensen O, Spasojevic M, Rashid G, Lundstrøm N, Gjertsen TJ, Aksnes AK, Bruland ØS(2024) Eighteen-Months Safety and Efficacy Following Intraperitoneal Treatment With 224Radium-Labeled Microparticles After CRS-HIPEC in Patients With Peritoneal Metastasis From Colorectal Cancer J Surg Oncol, 130(6), 1395-1402 DOI 10.1002/jso.27897, PubMed 39428687
